Single-crystal XRD: complete structural information, one crystal at a time

Single-crystal X-ray diffraction (SC-XRD) delivers the most complete structural picture available. By directing an X-ray beam at a single crystal and collecting diffraction data from multiple orientations, it yields the full three-dimensional crystal structure: unit cell parameters, space group, and atomic positions. This is the definitive answer to what polymorph you have, how the molecule packs, and what the conformation is.

The constraint is physical. SC-XRD requires a crystal large enough to generate sufficient diffraction signal – typically tens to hundreds of micrometres. A compound that forms only nanocrystals, or whose crystal size has been reduced by milling or spray drying, cannot be mounted and measured. When crystals are too small, the structural question simply goes unanswered.

X-ray powder diffraction: bulk phase characterization, but with limitations

X-ray powder diffraction (XRPD) takes a different approach entirely. It measures the combined diffraction signal from millions of crystals in a bulk powder – the material as it actually exists in development and manufacturing. The output is a characteristic diffraction pattern that identifies the dominant crystalline phases present across the whole sample. XRPD is the standard tool for confirming solid form in a manufactured batch, monitoring form changes during process development, and supporting regulatory submissions. For regulatory requirements relating to XRPD in pharmaceutical development, see the ICH Q6A guideline.

In principle, crystal structure determination is also possible from powder diffraction data. Methods exist to index the pattern, determine the unit cell, and solve and refine a structure from the resulting data. In practice, this is technically demanding. It requires high-quality data, a pure sample, and considerable expertise in powder crystallography. The process is sensitive to peak overlap – a consequence of the one-dimensional nature of a powder pattern compared to the three-dimensional data available from a single crystal – and ambiguities in indexing and structure solution multiply when data quality is imperfect.

These challenges become substantially harder when the sample is not phase pure. If a minority crystalline phase is present alongside the dominant form, its reflections overlap with those of the majority phase, complicating unit cell determination and making structure solution from the powder pattern unreliable or impossible without additional information. The practical limit is compounded by a concentration issue: phases present at below approximately 1–5% by mass are often not reliably detected at all, and the exact limit of detection for a specific minority phase in a specific matrix is not known in advance and must be empirically established. A trace polymorph at that level may be present and consequential – for stability, bioavailability, or intellectual property – while remaining invisible to the bulk measurement.

The gap between the two methods

Put simply: SC-XRD delivers full structural information but requires large, well-formed single crystals. XRPD works with the powders that pharmaceutical development actually produces but provides bulk-level phase data without single-crystal structural resolution, structure solution from powder is only feasible under favorable conditions, and minority phases may fall below detection limits. For many compounds under routine development conditions, that gap creates no problem. But for a nanocrystalline API, a compound with suspected trace polymorphism, or a material where XRPD yields ambiguous or incomplete results, the gap matters.

3D electron diffraction: structural resolution applied to powder-scale samples

This is where electron diffraction enters – not as a replacement for either X-ray method, but as the technique that connects the two.

Electrons interact with matter roughly 1,000 times more strongly than X-rays of comparable energy. In 3D electron diffraction (3D-ED), a focused electron beam is directed at an individual crystal in a standard powder sample – typically 50–1000 nm thick – while the sample is continuously rotated. Diffraction data from multiple orientations of that single crystal yields the same output as SC-XRD: unit cell parameters, space group, and atomic positions [1]. The full crystal structure, solved from a crystal too small to mount in an X-ray diffractometer, from the same powder you would submit for XRPD.

That combination – single-crystal structural resolution, applied to the nanocrystalline and powder materials that XRPD works with – is what opens capabilities that neither X-ray method can offer alone.

How can this become useful for the pharmaceutical industry?

Because 3D-ED delivers single-crystal structural resolution from standard powder samples, it opens several applications that are either inaccessible or unreliable with X-ray methods alone. The following are the core areas where ELDICO’s CRO service adds value in pharmaceutical development.

Many active pharmaceutical ingredients form only nanocrystals during synthesis, spray drying, or milling – crystals too small to mount for SC-XRD. 3D-ED solves the full structure directly from these materials, providing unit cell parameters, space group, and atomic positions without requiring a larger crystal.

Example: dabigatran etexilate mesylate (the active ingredient in Pradaxa) exists in multiple polymorphic forms. Two anhydrous forms and a hemihydrate were characterized in full using 3D-ED – including complete crystal structures of all three room-temperature-accessible forms – directly from nanocrystalline powder, without the need for large single crystals. The study provided the structural basis for selecting anhydrous form I for development, despite it being metastable, based on its superior bulk processing properties and demonstrated long-term stability [4].

• Applicable at any stage where crystal growth to X-ray size is not feasible
• Deliverable: CIF structure file, data quality report, publication-ready figures on request
• Typical turnaround: 2-4 weeks from sample receipt
• Supports pharmaceutical form selection, CMC package development, and IP landscape mapping
• Deliverable: form identification report, comparative structural analysis, recommendations for further study
• Applicable to process impurity identification, degradation product characterization, and raw material qualification
• Detection not limited by concentration – limited only by the number of crystals surveyed
• Relevant for amorphous solid dispersions, spray-dried intermediates, and milled materials
• Provides structural identity of nanocrystalline domains, not just detection

Different crystal forms of the same molecule can differ substantially in solubility, stability, and bioavailability. Identifying all relevant forms – and understanding their structures – is a core requirement of pharmaceutical solid-form development and IP protection. 3D-ED characterizes each form individually at the structural level, including forms present as minor components that XRPD may not resolve.

Example: in a collaboration with Ardena, 3D-ED was applied to characterize multiple solid forms of a pharmaceutical compound where XRPD patterns could not be resolved independently. Electron diffraction identified each form at single-crystal resolution, providing structural data that supported form selection and CMC decision-making [5]. 

Because 3D-ED operates crystal by crystal, concentration in the bulk sample is not a limiting factor. A minority crystalline phase – a trace polymorph, a process impurity, a degradant – that falls below XRPD’s detection limit is structurally accessible if a crystal of that phase can be located and measured. Automated data collection increases the number of crystals surveyed, which directly increases the probability of detecting and characterizing rare phases [2].

Example: automated 3D-ED experiments on a commercial sample of dapsone – an antimicrobial API with five previously known polymorphic forms – surveyed approximately 650 individual crystals in 24 hours. Around 3% of crystals returned an unknown unit cell. Structure solution confirmed a new polymorphic form (Form VI) of Dapsone, crystallizing in the monoclinic P2(1) space group with four independent molecules in the asymmetric unit – a form not predicted by prior computational screening [6]. In a separate study, 3D-ED was used to solve the crystal structure of ritonavir form 4, a metastable polymorph that had resisted characterization since its discovery and could not be isolated as a single crystal of sufficient size for SC-XRD. The structure was solved by combining 3D-ED data with crystal structure prediction and experimental XRPD, revealing a disordered motif and confirming the form is thermodynamically less stable than forms 1 and 2 [7].

Materials that appear amorphous or poorly crystalline by XRPD may contain discrete nanocrystalline domains that are structurally ordered at the local level. This distinction matters in formulation and stability work: the presence of nanocrystalline nuclei in an ostensibly amorphous matrix can be a precursor to crystallization on storage, with direct consequences for bioavailability and shelf life.

An example is a case study by ELDICO Scientific and RCPE, which compared melt quenching and ball milling as preparation techniques for amorphous APIs, using Carvedilol as a model compound. Using automated electron diffraction crystal mapping, ~100 particles per sample were analyzed on a TEM grid. The melt-quenched sample proved fully amorphous, while the ball-milled sample still contained residual crystallinity, detectable and matchable to the Carvedilol unit cell. This not only demonstrated that ball milling time needed to be extended, but also showcased how sensitive electron diffraction crystal mapping is in detecting trace crystalline phases — critical for ensuring product quality and regulatory compliance.  [2].

A complete workflow

XRPD remains the right tool for bulk phase characterization. SC-XRD remains the gold standard where large single crystals are available. 3D-ED adds the capability that connects them: structural information from the powders and nanocrystalline materials that conventional X-ray methods cannot fully address. The three methods are complementary, and a complete solid-form characterization strategy for a compound with meaningful polymorphic risk will typically draw on more than one.

If characterization is incomplete

 ELDICO’s CRO service provides easy access to 3D electron diffraction without the need for in-house instrumentation. If you’re working with a nanocrystalline API, a compound where SC-XRD has not been achievable, XRPD results are ambiguous, or minority phase detection is a concern — ELDICO is you partner. A free feasibility testing is available, making it straightforward to explore whether 3D electron diffraction is the right solution for your sample.

We’re happy to discuss the sample and whether electron diffraction is the appropriate next step before any project commitment.

Contact us: sales@eldico.ch

References

[1] Simoncic, P., Romeijn, E., Hovestreydt, E., Steinfeld, G., Santiso-Quiñones, G. & Merkelbach, J. Electron crystallography and dedicated electron-diffraction instrumentation. Acta Cryst. E79, 410–422 (2023). https://doi.org/10.1107/S2056989023003109

[2] Merkelbach, J., Stam, D., Jandl, C., Kushwah, V., Paudel, A. & Simoncic, P. Crystal mapping using the ELDICO ED-1 electron diffractometer. Imaging & Microscopy (2023). https://analyticalscience.wiley.com/do/10.1002/was.0004000393

[3] Holzwarth, U. & Gibson, N. The Scherrer equation versus the ‘Debye–Scherrer equation’. Nat. Nanotechnol. 6, 534 (2011). https://doi.org/10.1038/nnano.2011.145

[4] Sieger, P., Werthmann, U. & Saouane, S. The polymorph landscape of dabigatran etexilate mesylate: Taking the challenge to bring a metastable polymorph to market. European Journal of Pharmaceutical Sciences, 186, 106447 (2023). https://doi.org/10.1016/j.ejps.2023.106447

[5] ELDICO Scientific AG & Ardena. Application note: solid form characterisation by 3D electron diffraction. Available on request from ELDICO Scientific.

[6] ELDICO Scientific AG. New polymorphic form of dapsone found with automated electron diffraction (microED) experiments on a commercial sample. Application Note AN18 (2025). https://5756737.fs1.hubspotusercontent-na1.net/hubfs/5756737/application%20notes/AN18%20-%20ELDICO-AutomatedED-Dapsone.pdf

[7] Iuzzolino, L., Kelly, A.W., Chaudhry, M.T., Jandl, C., Stam, D. et al. Predicting the ritonavir crisis by revisiting the polymorph landscape with crystal structure prediction and form 4 structure solution. Communications Chemistry, 8, 404 (2025). https://doi.org/10.1038/s42004-025-01814-6

The post Electron Diffraction: The Missing Link Between SC-XRD and XRPD first appeared on ELDICO Scientific AG.

The pharmaceutical industry continues to demand faster and more reliable solid-state insights. ELDICO’s ED-1 system is designed specifically for automated, high-throughput operation with minimal supervision, reducing operator time and improving data consistency. Its ability to work from native nanocrystals provides a clear industrial advantage across API development, formulation, and broader R&D environments.

“Partnering with ELDICO Scientific further strengthens our industry-leading offerings in materials characterization by adding electron diffraction techniques.” stated Aashish Chourey, Director of Business Development for Quantum Design. “We look forward to providing the comprehensive sales & service support needed to take the ELDICO ED-1 to global markets.”

With Quantum Design’s established global reach and ELDICO’s dedicated electron diffraction technology, customers gain easier access to high-quality structural analysis capabilities and stronger support for scaling ED workflows.

“This partnership marks an important moment for both Quantum Design and ELDICO,” said Dr James Berwick, CEO of ELDICO Scientific. “We have established ourselves as the leading provider of industrial electron diffraction solutions to the pharmaceutical sector, and this collaboration allows us to build on that position. By combining Quantum Design’s global reach with our dedicated ED technology, we can expand access to high-quality structural analysis and create new opportunities for customers across research and industry. We look forward to presenting our joint capabilities at major conferences and exhibitions throughout 2026 and in the years ahead.”

Together, Quantum Design and ELDICO will accelerate the global adoption of electron diffraction for industrial and scientific decision-making. 

About Quantum Design

Founded in 1982, Quantum Design is a privately held corporation that develops and markets advanced technology, cryogenic systems and characterization instruments for the scientific community. Quantum Design is widely recognized as the leading commercial source for integrated laboratory analytical systems incorporating superconducting technology. In addition, through its strong R&D focus and direct foreign offices in the world’s major technology markets, Quantum Design has developed a worldwide sales and support network for its own industry leading instruments as well as for research-based instruments developed by other technology leaders. 

The post Quantum Design and ELDICO Scientific Announce Distribution Agreement first appeared on ELDICO Scientific AG.

Dr. James Berwick CEO at Eldico Scientific, anticipates that the new ELDICO Crystallographic Expert Solutions and Services will become a key player in the market. This integrated approach offers a comprehensive range of crystallographic services, built on Eldico’s cutting-edge equipment and Crystallise!’s proven ability to grow high-quality crystals from small molecule samples. Dr. Gustavo Santiso-Quinones, CTO of Crystallise!, highlights the company’s 85% success rate in crystallization for structural elucidation.
The combined expertise of the two companies offers a broad spectrum of crystallographic analysis, including:

• Electron diffraction (3D ED/microED) for rapid and accurate structure determination of nanoparticles
• Crystal mapping for quick unit cell determination and identification
• Inert transfer and low-temperature measurements
• Impurity, polymorph, and phase identification
• Characterization of co-crystals, salts, and amorphous solid dispersions

In addition to these capabilities, Crystallise! brings extensive experience with X-ray diffraction (SC-XRD) techniques, offering services such as:

• Successful crystal growth for structural elucidation
• Crystallization of specific polymorphs, hydrates, and solvates
• Cryogenic handling of sensitive compounds from mother liquor
• Crystallization from as little as 5 mg of sample
• And other specialized techniques

Noteworthy offerings from this partnership include:
• Crystallization with as little as 100 μg of sample for electron diffraction
• Efficient enhancement of crystallinity in nano-powders for structural analysis
• Crystallization and structural elucidation of natural products and metabolites with minimal sample availability
• New solutions tailored for the pharmaceutical and agrochemical industries, aimed at accelerating drug development

Dr. Gunther Steinfeld and Dr. Gustavo Santiso-Q, founders of both companies, emphasized that this collaboration effectively unites complementary strengths, with even more innovations expected in the future.

About Eldico Scientific:
Eldico Scientific is a leading provider of advanced electron diffraction solutions, dedicated to empowering researchers to gain precise insights into the atomic and molecular structure of crystalline compounds. With state-of-the-art electron diffraction instruments and customer centred services, Eldico Scientific empowers scientists and industries to push the frontiers of pharmaceutical, chemical and materials research.

Website: www.eldico-scientific.com 

About Crystallise!
Crystallise! is a leader in providing crystallization services to pharmaceutical industry and life sciences industries. The company provides solutions to accelerate innovation and ensure the highest quality standards in drug development.

Website: Crystallise! AG Crystallization Services, X-ray & Electron Diffraction (micro-ED)

For media inquiries, please contact:
Eldico:
Danny Stam, Sales Manager
stam@eldico.ch 

For media inquiries, please contact:
Crystallise!
Gustavo Santiso-Quinones, CTO
santiso@eldico.ch 

info@crystallise.ch

ELDICO`s CEO Dr. James Berwick, together with Dr. Gustavo Santiso-Quinones, CTO of Crystallise!

The post The new CRO for structural elucidation and more… first appeared on ELDICO Scientific AG.

Holodiag’s adoption of Eldico’s electron diffractometer highlights the increasing demand for precise and efficient tools in analyzing challenging materials for the Pharmaceutical Industry. The ELDICO ED-1 will be deployed not only for solving crystal structures of nanocrystals but also in finding phase impurities and crystalline traces in amorphous substances and elucidating molecular structures, all critical steps for drug development and quality assurance. Eldico’s electron diffraction technology offers unmatched accuracy, efficiency, and reliability, enabling companies like Holodiag to elevate their research analysis capabilities.

“This partnership with Holodiag underscores the transformative potential of electron diffraction in the pharmaceutical industry,” said Dr. James Berwick CEO at Eldico Scientific. “We are excited to see our technology driving innovation in material analysis and contributing to the development of safer, more effective pharmaceutical products. It is also impressive how contract research organisations are driving this change adding electron diffraction to their portfolio of analytical devices”

“We are thrilled to integrate Eldico Scientific’s state-of-the-art electron diffractometer into our operations,” said Pierric Marchand Founder and General Manager of Holodiag. “This instrument is a game-changer for our work in analyzing nanocrystalline and complex pharmaceutical materials. It not only improves our efficiency but also ensures unparalleled accuracy in our research and quality assurance processes. We look forward to leveraging this technology to better serve our clients and accelerate advancements in the pharmaceutical industry.”

About Eldico Scientific:
Eldico Scientific is a leading provider of advanced electron diffraction solutions, dedicated to empowering researchers to gain precise insights into the atomic and molecular structure of crystalline compounds. With state-of-the-art electron diffraction instruments and customer centred services, Eldico Scientific empowers scientists and industries to push the frontiers of pharmaceutical, chemical and materials research.

Website: www.eldico-scientific.com 

About Holodiag:
Holodiag is a leader in providing solid and crystallization services to pharmaceutical industry with a strong focus on material analysis and life sciences industries. The company provides high-precision material characterization solutions to accelerate innovation and ensure the highest quality standards in drug development. Since July 2024, the Italian CDMO Icrom has acquired Holodiag, now both being part of Proxis Development, a French industrial group.

Website: www.holodiag.com

For media inquiries, please contact:
Eldico:
Alessia Portieri, Sales Manager
portieri@eldico.ch 

Holodiag
Pierric Marchand, CEO

pierric.marchand@holodiag.com

ELDICO ED-1

The post ELDICO Scientific announces sale to Holodiag first appeared on ELDICO Scientific AG.

Quantum Design China, a subsidiary of Quantum Design International, is renowned for its expertise in representing and distributing advanced scientific instruments from global leaders and it has a very strong reputation to establish networks and penetrate market in China for new brands effectively. “We are excited with the partnership, as the cutting-edge electron diffraction solutions from Eldico Scientific would enable the crystallographer to directly identify previously unsolvable structures from nanocrystalline material, and open up perspectives for preparative chemistry and pharmacy, electrochemistry, agrochemistry and specialty chemistry that were unimaginable until recently” Said Mr. Lambert Cao, the Managing Director of Quantum Design China.  “The partnership with Eldico Scientific underscores our dedication to bringing latest revolutionary technologies into China research and development communities!”

About Eldico Scientific:
Eldico Scientific is a leading provider of advanced electron diffraction solutions, dedicated to empowering researchers to gain precise insights into the atomic and molecular structure of crystalline compounds. With state-of-the-art electron diffraction instruments and customer-centered services, Eldico Scientific empowers scientists and industries to push the frontiers of pharmaceutical, chemical and materials research.

Website: www.eldico-scientific.com 

About Quantum Design China:
Quantum Design China is a leading distributor of high-quality scientific instruments, providing innovative solutions and exceptional support to researchers and industries in China. As part of Quantum Design International, the company upholds a commitment to advancing science through technology.

Website: Quantum Design

For media inquiries, please contact:
Eldico:
Alessia Portieri, Sales Manager
portieri@eldico.ch 

Quantum Design China
Lambert Cao, Managing Director
lambert@qd-china.com

ELDICO ED-1 electron diffractometer

The post ELDICO SCIENTIFIC announces partnership with Quantum Design China first appeared on ELDICO Scientific AG.

The ELDICO ED-1 provides faster results compared to traditional X-ray crystallography as it bypasses the need to grow large crystals providing structure elucidation within minutes. Its cutting-edge continuous rotation technology will allow Triclinic Labs to expand its services, especially for clients in pharmaceuticals, materials science, and generally chemistry, providing also a chance to search for impurities in powders.

Dr. James Berwick, CEO of ELDICO, emphasized that this installation represents a significant step in our global expansion and will be key to positioning the ELDICO ED-1, as the premier solution for advanced crystallographic research in U.S.A.

“We’ve already started to collect data using the ELDICO ED-1. Along with enabling us to provide structural information using crystals that are too small for single-crystal experiments, we’ve integrated MicroED into our solid form screening and materials characterization workflows. We’re getting data we previously couldn’t provide. It allows us to make decisions much earlier – which is really exciting and enabling for our clients,” said Dr. Steef Boerrigter, Research Fellow and head crystallographer at Triclinic Labs.”

About Eldico Scientific:
Eldico Scientific is a leading provider of advanced electron diffraction solutions, dedicated to empowering researchers to gain precise insights into the atomic and molecular structure of crystalline compounds. With state-of-the-art electron diffraction instruments and customer-centered services, Eldico Scientific empowers scientists and industries to push the frontiers of pharmaceutical, chemical and materials research.

Website: www.eldico-scientific.com 

About Triclinic Labs:
Triclinic Labs, a prominent contract research organization (CRO), specializes in advanced solid-state chemistry, materials science, and pharmaceutical development. Known for its scientific expertise and commitment to innovation, Triclinic Labs assists clients in the pharmaceutical, specialty chemical, and consumer goods industries by delivering high-quality, data-driven insights into materials’ properties, polymorphism, and stability.

Website: www.tricliniclabs.com

For media inquiries, please contact:
Eldico:
Alessia Portieri, Sales Manager
portieri@eldico.ch 

TriclinicLabs
Steef Boerrigter, Head crystallographer
scomella@tricliniclabs.com

The post ELDICO Scientific announces succesful installation at Triclinic Labs first appeared on ELDICO Scientific AG.

This partnership aligns the strengths of both organizations, combining ELDICO’s advanced diffractometer with Spectek’s extensive distribution network and deep market expertise, marking a significant step forward for both companies in expanding their global reach. 

“We are excited to partner with Spectek to expand our product offerings into new markets, particularly in India. With the ‘Make in India’ initiative transforming the country into a global powerhouse for API and intermediate production, the demand for MicroED technology has never been stronger,” said Dr. James Berwick, CEO of ELDICO. “Spectek’s proven distribution capabilities and technical expertise align perfectly with our vision of providing superior solutions and support to our customers. This collaboration marks a significant milestone in our growth strategy.” 

Spectek’s Managing Director, Prasanna Krishnan, also expressed enthusiasm for the partnership, stating, “ELDICO’s industry-leading dedicated electron diffractometer complements our portfolio, and we’re confident that this partnership will bring tremendous value to our clients. We look forward to a fruitful collaboration that will enhance access to not only products across our network but also Measurement as a Service (MaaS) requests.” 

About Eldico Scientific:
Eldico Scientific is a leading provider of advanced electron diffraction solutions, dedicated to empowering researchers to gain precise insights into the atomic and molecular structure of crystalline compounds. With state-of-the-art electron diffraction instruments and customer-centered services, Eldico Scientific empowers scientists and industries to push the frontiers of pharmaceutical, chemical and materials research.

Website: www.eldico-scientific.com 

About Spectek:
Spectek Instruments is a supplier of Analytical Instruments, providing reliable and robust solutions in the field of Material Testing. We partner with some of the leading Analytical Instrumentation companies from around the globe to deliver consultative and application based solutions to our customers. Spectek is a young and dynamic organization, providing reliable and robust solutions in the field of Material Testing.

Website: www.spectek.co.in

For media inquiries, please contact:
Eldico:
Alessia Portieri, Sales Manager
portieri@eldico.ch 

Spectek Instruments Pvt.Ltd.
Prasanna Krishnan, Managing Director
prasanna.krishnan@spectek.co.in

The post Eldico and Spectek announce strategic partnership to expand distribution network  first appeared on ELDICO Scientific AG.

The post ELDICO Scientific and TeraCrystal announce strategic partnership first appeared on ELDICO Scientific AG.

Triclinic Labs and ELDICO Scientific are committed to pushing the boundaries of structural analysis and fostering innovation in their respective fields. This sale represents a significant step forward in the pursuit of ground-breaking discoveries and advancements in pharmaceuticals and materials science.

www.eldico-scientific.com

The post ELDICO Scientific and TriClinic Labs, Inc.    announce collaboration first appeared on ELDICO Scientific AG.

Electron Diffractometer delivered to Max-Planck-Institut für Kohlenforschung, in Mülheim an der Ruhr, Germany.

ELDICO Scientific AG is happy to announce the successful delivery and installation of the ED-1 at the Max-Planck-Institut für Kohlenforschung, in Mülheim an der Ruhr, Germany.

The new large scale instrument has been provided to evaluate whether it can usefully complement the analytical capabilities of the Institute’s Chemical Crystallography department. The ELDICO ED-1  will extent the existing range of techniques, including SC-XRD, PXRD, SEM and TEM, broadening the range of solid compound analysis available to researchers at the MPI für Kohlenforschung.

What sets the ELDICO ED-1 apart is its ability to provide crystal structure analysis from micrograms of sample material (nanocrystals). This capability opens up new avenues of exploration for researchers across the various fields in the institute working on heterogenic catalysis, organo-catalysis, organometallic chemistry, and organic chemistry among other areas of catalysis.

The advantages offered by the ELDICO ED-1 are expected to accelerate breakthroughs in the research endeavors, enabling the institute to gain deeper insights into the properties and behaviors of solid compounds.

Eldico Scientific is pleased to be able to accompany this evaluation: Looking ahead, we’re excited about the possibilities for continued collaboration and the impact we can make together. Whether it’s through ongoing support, further enhancements, or new initiatives, we’re committed to advancing our shared goals.

ELDICO ED-1 enables a wide range of sophisticated crystallographic experiments

ELDICO ED-1‘s capabilities have been well received by the audience, which recognized it as an invaluable tool for characterizing nanomaterials, assisting in quality control and accelerating research and development times. Additionally, the availability of a “cryo” option, combined with an easy-to-handle cryo transfer system, enables a wide range of sophisticated crystallographic experiments and will expand our application field to include studies of solvent-framework interactions and phase transition crystals.

To gain deeper insights into our perspective and the evolving landscape of electron diffraction, explore our website and contact our scientific and team at sales@eldico.ch. We look forward to hearing from you!

The post Delivery of ELDICO ED-1 to Max-Planck-Institut für Kohlenforschung, in Mülheim an der Ruhr, Germany first appeared on ELDICO Scientific AG.